Pharmaceutical composition for treating inflammation and pain
The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ω-(methylthio)alkylnitriles such as 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition according to claim 1 , wherein the compound has at least 90% (w/w) purity, and the composition is in a topical form of gels, creams, lotions, ointments, or patches.
3. The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate, diethylene glycol monoethyl ether, caprylic/capric triglyceride, octisalate, silicone fluid, squalene, and sunflower oil.
4. The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethyl ether.
5. The pharmaceutical composition according to claim 2 , comprising diethylene glycol monoethyl ether, acrylates/C10-30 alkyl acrylate polymer, and tris(2-hydroxyethyl)amine.
6. The pharmaceutical composition according to claim 1 , wherein the compound has at least 90% (w/w) purity, and the composition is in an oral form of tablets, capsules, or syrup.
7. The pharmaceutical composition according to claim 6 , wherein the composition is in an oral form of tablets, capsules, or syrups.